Nykode Therapeutics Dividends and Buybacks
Dividend criteria checks 2/6
Nykode Therapeutics is a dividend paying company with a current yield of 45%.
Key information
45.0%
Dividend yield
-64.6%
Buyback Yield
| Total Shareholder Yield | -19.6% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | -241% |
Recent dividend and buyback updates
Recent updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Too early to tell whether NYKD's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if NYKD's dividend payments are increasing as they only just started paying a dividend.
Dividend Yield vs Market
| Nykode Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NYKD) | 45.0% |
| Market Bottom 25% (NO) | 3.2% |
| Market Top 25% (NO) | 8.9% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (NYKD) (up to 3 years) | 0% |
Notable Dividend: NYKD's dividend (45%) is higher than the bottom 25% of dividend payers in the Norwegian market (3.16%).
High Dividend: NYKD's dividend (45%) is in the top 25% of dividend payers in the Norwegian market (8.91%)
Earnings Payout to Shareholders
Earnings Coverage: NYKD is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: NYKD is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/28 10:21 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nykode Therapeutics AS is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Viktor Sundberg | ABG Sundal Collier Sponsored |
| Geir Holom | DNB Carnegie |
| Lucy Codrington | Jefferies LLC |